(Good News from Finland) The BioFood method, developed by Biohit, has been granted a patent in the United States. The method aims at reducing the amount of acetaldehyde exposure through food intake, which is the single most significant factor in the development of cancers in the upper gastrointestinal tract.
The invention comprises a food composition that contains an acetaldehyde-binding component. Its aim is to decrease the detrimental acetaldehyde content in the mouth, the pharynx, the oesophagus, the stomach, and the small and large intestines, and through this to reduce the risk of cancer in these areas.
Nearly one and a half million people die from upper gastrointestinal tract cancers each year, which makes them the single most important cause of cancer-related deaths. The prognosis for these types of cancers is exceptionally poor. The key, therefore, lies in their prevention and early diagnosis.
Biohit HealthCare is a Finnish biotechnology company established in 1988. It is specialised in the diagnostics and prevention of diseases of the gastrointestinal tract. The company’s products have been granted multiple patents worldwide.